A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer

被引：0
|
作者：
Burzykowski, T
Piccart, MJ
Sledge, G
Carmichael, J
Luck, HJ
Mackey, JR
Nabholtz, JM
Paridaens, R
Biganzoli, L
Jassem, J
Blohmer, JU
Bontenbal, M
Bonneterre, J
Chan, S
Atalay, G
Therasse, P
Buyse, M
机构：
[1] Limburgs Univ Centrum, Diepenbeek, Belgium
[2] Inst Jules Bordet, B-1000 Brussels, Belgium
[3] IDDI, Brussels, Belgium
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S277 / S278
页数：2
相关论文
共 50 条
  • [21] Spatial heterogeneity of MRI response to first-line hormonal therapy to predict progression-free survival in metastatic breast cancer.
    Kosmin, Michael
    Makris, Andreas
    Sokhi, Heminder
    Thijssen, Toon
    Padhani, Anwar R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer
    Elia, E. G.
    Staedler, N.
    Ciani, O.
    Taylor, R. S.
    Bujkiewicz, S.
    CANCER EPIDEMIOLOGY, 2020, 64
  • [23] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    CANCER RESEARCH, 2018, 78 (13)
  • [24] Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
    Amdahl, Jordan
    Chen, Lei
    Delea, Thomas E.
    ONCOLOGY AND THERAPY, 2016, 4 (02) : 239 - 256
  • [25] Estimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer
    Bowater, Russell J.
    Lilford, Philippa E.
    Lilford, Richard J.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2011, 27 (03) : 207 - 214
  • [26] Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
    Jordan Amdahl
    Lei Chen
    Thomas E. Delea
    Oncology and Therapy, 2016, 4 (2) : 239 - 256
  • [27] PERSONALIZED DISCRETE EVENT SIMULATION OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL FOR FIRST-LINE DOUBLET CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER
    Degeling, K.
    Wong, H. L.
    Johns, J.
    Koffijberg, H.
    Gibbs, P.
    IJzerman, M.
    VALUE IN HEALTH, 2019, 22 : S96 - S96
  • [28] Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
    Imai, Hisao
    Mori, Keita
    Wakuda, Kazushige
    Ono, Akira
    Akamatsu, Hiroaki
    Shukuya, Takehito
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Kaira, Kyoichi
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    ANNALS OF THORACIC MEDICINE, 2015, 10 (01) : 61 - 66
  • [29] BEVACIZUMABIN AND FIRST-LINE CHEMOTHERAPY IN THE TREATMENT OF METASTATIC COLORECTAL CANCER: EVALUATION OF CLINICAL EFFICACY AND PROGRESSION-FREE SURVIVAL
    Liang, Jinhao
    Xiang, Chengjiang
    Sun, Ke
    FARMACIA, 2023, 71 (04) : 747 - 754
  • [30] Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival
    Simone De Leo
    Marta Di Stefano
    Luca Persani
    Laura Fugazzola
    Carla Colombo
    Endocrine, 2021, 72 : 462 - 469
12345